Combination of urea-crosslinked hyaluronic acid and sodium ascorbyl phosphate for the treatment of inflammatory lung diseases: an in vitro study

Arianna Fallacara, Laura Busato, Michele Pozzoli, Maliheh Ghadiri, Hui Xin Ong, Paul M. Young, Stefano Manfredini, Daniela Traini

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)

Abstract

This in vitro study evaluated, for the first time, the safety and the biological activity of a novel urea-crosslinked hyaluronic acid component and sodium ascorbyl phosphate (HA-CL – SAP), singularly and/or in combination, intended for the treatment of inflammatory lung diseases. The aim was to understand if the combination HA-CL – SAP had an enhanced activity with respect to the combination native hyaluronic acid (HA) – SAP and the single SAP, HA and HA-CL components. Sample solutions displayed pH, osmolality and viscosity values suitable for lung delivery and showed to be not toxic on epithelial Calu-3 cells at the concentrations used in this study. The HA-CL – SAP displayed the most significant reduction in interleukin-6 (IL-6) and reactive oxygen species (ROS) levels, due to the combined action of HA-CL and SAP. Moreover, this combination showed improved cellular healing (wound closure) with respect to HA – SAP, SAP and HA, although at a lower rate than HA-CL alone. These preliminary results showed that the combination HA-CL - SAP could be suitable to reduce inflammation and oxidative stress in lung disorders like acute respiratory distress syndrome, asthma, emphysema and chronic obstructive pulmonary disease, where inflammation is prominent.
Original languageEnglish
Pages (from-to)96-106
Number of pages11
JournalEuropean Journal of Pharmaceutical Sciences
Volume120
DOIs
Publication statusPublished - 30 Jul 2018
Externally publishedYes

Keywords

  • Anti-inflammatory
  • Antioxidant
  • Hyaluronic acid
  • Sodium ascorbyl phosphate
  • Urea-crosslinked hyaluronic acid
  • Wound healing

Fingerprint

Dive into the research topics of 'Combination of urea-crosslinked hyaluronic acid and sodium ascorbyl phosphate for the treatment of inflammatory lung diseases: an in vitro study'. Together they form a unique fingerprint.

Cite this